Table of Contents List of Tables List of Figures Introduction Global Markets Direct Report Coverage Kinesin Like Protein KIF11 (Kinesin Like Protein 1 or Kinesin Like Spindle Protein HKSP or Kinesin Related Motor Protein Eg5 or Thyroid Receptor Interacting Protein 5 or TRIP5 or EG5 or KIF11) - Overview Kinesin Like Protein KIF11 (Kinesin Like Protein 1 or Kinesin Like Spindle Protein HKSP or Kinesin Related Motor Protein Eg5 or Thyroid Receptor Interacting Protein 5 or TRIP5 or EG5 or KIF11) - Therapeutics Development Products under Development by Stage of Development Products under Development by Therapy Area Products under Development by Indication Products under Development by Companies Products under Development by Universities/Institutes Kinesin Like Protein KIF11 (Kinesin Like Protein 1 or Kinesin Like Spindle Protein HKSP or Kinesin Related Motor Protein Eg5 or Thyroid Receptor Interacting Protein 5 or TRIP5 or EG5 or KIF11) - Therapeutics Assessment Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Kinesin Like Protein KIF11 (Kinesin Like Protein 1 or Kinesin Like Spindle Protein HKSP or Kinesin Related Motor Protein Eg5 or Thyroid Receptor Interacting Protein 5 or TRIP5 or EG5 or KIF11) - Companies Involved in Therapeutics Development 4SC AG Kyowa Hakko Kirin Co Ltd Merck & Co Inc Novartis AG Kinesin Like Protein KIF11 (Kinesin Like Protein 1 or Kinesin Like Spindle Protein HKSP or Kinesin Related Motor Protein Eg5 or Thyroid Receptor Interacting Protein 5 or TRIP5 or EG5 or KIF11) - Drug Profiles 4SC-205 - Drug Profile Product Description Mechanism Of Action R&D Progress BQS-481 - Drug Profile Product Description Mechanism Of Action R&D Progress MK-8267 - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit Eg5 for Immunology and Oncology - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit KSP for Oncology - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit Mitotic Kinesin Eg5 for Ovarian Cancer - Drug Profile Product Description Mechanism Of Action R&D Progress SRI-35566 - Drug Profile Product Description Mechanism Of Action R&D Progress Kinesin Like Protein KIF11 (Kinesin Like Protein 1 or Kinesin Like Spindle Protein HKSP or Kinesin Related Motor Protein Eg5 or Thyroid Receptor Interacting Protein 5 or TRIP5 or EG5 or KIF11) - Dormant Products Kinesin Like Protein KIF11 (Kinesin Like Protein 1 or Kinesin Like Spindle Protein HKSP or Kinesin Related Motor Protein Eg5 or Thyroid Receptor Interacting Protein 5 or TRIP5 or EG5 or KIF11) - Discontinued Products Kinesin Like Protein KIF11 (Kinesin Like Protein 1 or Kinesin Like Spindle Protein HKSP or Kinesin Related Motor Protein Eg5 or Thyroid Receptor Interacting Protein 5 or TRIP5 or EG5 or KIF11) - Product Development Milestones Featured News & Press Releases Jun 03, 2015: 4SC Presents Final Results From Phase I AEGIS Trial As Well As Rationale For Daily Dosing Scheme Of 4SC-205 Cancer Compound At ASCO Dec 09, 2014: 4SC reports positive topline data from clinical Phase I trial with 4SC-205 in cancer patients using novel continuous dosing scheme Jul 29, 2013: Motor Protein Revs Up Cell Division Jun 06, 2013: Leukemia & Lymphoma Society Honors Ohi’s Research Dec 05, 2012: 4SC Reports Positive Data From Clinical Phase I Trial With 4SC-205 In Cancer Patients And Initiates Study Amendment Feb 11, 2010: 4SC Announces Treatment Of First Patient In Phase I Study Of 4SC-205 Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer

List of Tables Number of Products under Development by Stage of Development, H2 2017 Number of Products under Development by Therapy Areas, H2 2017 Number of Products under Development by Indication, H2 2017 Number of Products under Development by Companies, H2 2017 Products under Development by Companies, H2 2017 Products under Development by Companies, H2 2017 (Contd..1), H2 2017 Number of Products under Investigation by Universities/Institutes, H2 2017 Products under Investigation by Universities/Institutes, H2 2017 Number of Products by Stage and Mechanism of Actions, H2 2017 Number of Products by Stage and Route of Administration, H2 2017 Number of Products by Stage and Molecule Type, H2 2017 Pipeline by 4SC AG, H2 2017 Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2017 Pipeline by Merck & Co Inc, H2 2017 Pipeline by Novartis AG, H2 2017 Dormant Products, H2 2017 Dormant Products, H2 2017 (Contd..1), H2 2017 Discontinued Products, H2 2017 List of Figures Number of Products under Development by Stage of Development, H2 2017 Number of Products under Development by Therapy Areas, H2 2017 Number of Products under Development by Top 10 Indications, H2 2017 Number of Products by Stage and Mechanism of Actions, H2 2017 Number of Products by Routes of Administration, H2 2017 Number of Products by Stage and Routes of Administration, H2 2017 Number of Products by Stage and Molecule Type, H2 2017

4SC AG Kyowa Hakko Kirin Co Ltd Merck & Co Inc Novartis AG